India, Sept. 16 -- Biotech stocks were in focus Wednesday following a series of company updates, including Tempest Therapeutics' new in vivo CAR-T licensing deal, DataMEDS AI's Helomics acquisition, expanded coverage for NeurAxis' PENFS therapy and MAIA Biotechnology's first U.S. patient dosing in its THIO-101 trial.
Read on.
DataMEDS AI (MEDS) shares are gaining over 300% after the company completed its acquisition of Helomics Corp. from Axe Compute, expanding into precision oncology and AI-powered cancer diagnostics. The deal includes a CLIA/CAP-certified laboratory, equipment, Predictive Oncology's CRO central lab services and $1.5 million in cash. DataMEDS plans to expand cancer screening, molecular profiling and laboratory services....